Literature DB >> 1495788

Contact transscleral Nd:YAG laser cyclophotocoagulation. Midterm results.

J S Schuman1, A R Bellows, B J Shingleton, M A Latina, R R Allingham, C D Belcher, C A Puliafito.   

Abstract

BACKGROUND: Early reports of both contact and noncontact transscleral Nd:YAG laser cyclophotocoagulation have been encouraging; however, recent evidence indicates a significant incidence of hypotony, visual loss, and phthisis with the noncontact technique with more than 6 months of follow-up. The authors sought to determine the intermediate term effects of contact transscleral Nd:YAG laser cyclophotocoagulation (CYC).
METHODS: The authors followed 116 eyes of 114 patients for a minimum of 1 year after treatment of advanced glaucoma with CYC.
RESULTS: The mean preoperative intraocular pressure (IOP) of 35.0 +/- 1.0 mmHg decreased to 18.6 +/- 1.1 mmHg (P less than 0.0001) during the average follow-up of 19.0 +/- 0.6 months (range, 12 to 36 months). Intraocular pressure control of 3 to 25 mmHg was achieved in 72%, 3 to 22 mmHg in 65%, and 3 to 19 mmHg in 56% of eyes. Retreatment was required in 31 of the 116 eyes (27%). Intraocular pressure decreased to less than 3 mmHg in 9 eyes and to 0 mmHg in 6 of these 9 eyes. Nineteen eyes, all with initial visual acuity of counting fingers or worse, progressed to no light perception; 17 of 36 eyes (47%) with visual acuity of 20/200 or better lost 2 or more Snellen lines.
CONCLUSION: Midterm results of CYC continue to be encouraging but are tempered by a nearly 10% incidence of hypotony or phthisis and the progression of visual loss.

Entities:  

Mesh:

Year:  1992        PMID: 1495788     DOI: 10.1016/s0161-6420(92)31846-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  13 in total

1.  Long term results of diode laser cycloablation in complex glaucoma using the Zeiss Visulas II system.

Authors:  S Ataullah; S Biswas; P H Artes; E O'Donoghue; A E A Ridgway; A F Spencer
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

2.  "Cyclodiode": results of a standard protocol.

Authors:  A F Spencer; S A Vernon
Journal:  Br J Ophthalmol       Date:  1999-03       Impact factor: 4.638

3.  Transvitreal endocyclophotocoagulation.

Authors:  J A Haller
Journal:  Trans Am Ophthalmol Soc       Date:  1996

4.  Contact transscleral neodymium:yttrium-aluminum-garnet laser cyclophotocoagulation Long-term outcome.

Authors:  Patty Lin; Gadi Wollstein; Ioannis P Glavas; Joel S Schuman
Journal:  Ophthalmology       Date:  2004-11       Impact factor: 12.079

5.  A two centre study of the dose-response relation for transscleral diode laser cyclophotocoagulation in refractory glaucoma.

Authors:  C C Murphy; C A M Burnett; P G D Spry; D C Broadway; J P Diamond
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

Review 6.  Endoscopic cyclophotocoagulation.

Authors:  S Lin
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

7.  Controlled Cyclophotocoagulation with diode laser in refractory glaucoma and long term follow up at King Abdulaziz University Hospital, Riyadh.

Authors:  Essam A Osman; Abdulrahman Al-Muammar; Ahmed Mousa; Hani Al-Mezaine; Saleh A Al-Obeidan
Journal:  Saudi J Ophthalmol       Date:  2010-01-07

8.  Vascular effects on ciliary tissue from endoscopic versus trans-scleral cyclophotocoagulation.

Authors:  S C Lin; M J Chen; M S Lin; E Howes; R L Stamper
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

9.  Clinical options for the reduction of elevated intraocular pressure.

Authors:  Laura Crawley; Sohaib M Zamir; Maria F Cordeiro; Li Guo
Journal:  Ophthalmol Eye Dis       Date:  2012-04-30

10.  A retrospective analysis of long-term outcomes following a single episode of transscleral cyclodiode laser treatment in patients with glaucoma.

Authors:  Ivailo Zhekov; Razia Janjua; Humma Shahid; Nicholas Sarkies; Keith R Martin; Andrew J R White
Journal:  BMJ Open       Date:  2013-07-06       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.